We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
Quote | Fortress Biotech Inc. (NASDAQ:FBIO)
Last: | $2.25 |
---|---|
Change Percent: | 0.0% |
Open: | $2.6 |
Close: | $2.25 |
High: | $2.6 |
Low: | $2.24 |
Volume: | 511,234 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Fortress Biotech Inc. (NASDAQ:FBIO)
2024-07-25 08:45:03 ET More on Fortress Biotech Fortress Biotech pauses dividend payments on preferred stock Seeking Alpha’s Quant Rating on Fortress Biotech Historical earnings data for Fortress Biotech Financial information for Fortress Biotech ...
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...
Message Board Posts | Fortress Biotech Inc. (NASDAQ:FBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FBIO News Article - Checkpoint Therapeutics Announces $6.1 Million Registered Direct O | whytestocks | investorshangout | 03/31/2023 5:40:56 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation Reports Full-Year 2022 Financial Resul | whytestocks | investorshangout | 03/29/2023 8:26:10 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation to Participate in the 35th Annual ROTH | whytestocks | investorshangout | 03/07/2023 6:35:47 PM |
Has $FBIO gotten a NASDAQ warning letter yet? | Spicknspan | investorshub | 02/28/2023 12:20:02 AM |
whytestocks: $FBIO News Article - Helocyte, Inc. Announces Positive Data from Stem Cell Transplant D | whytestocks | investorshangout | 02/16/2023 7:40:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...